Published in Heart Rhythm on February 13, 2010
Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov (2012) 1.42
ESCRT-dependent targeting of plasma membrane localized KCa3.1 to the lysosomes. Am J Physiol Cell Physiol (2010) 1.06
The Na+/K+ pump is an important modulator of refractoriness and rotor dynamics in human atrial tissue. Am J Physiol Heart Circ Physiol (2011) 0.94
Functional interaction with filamin A and intracellular Ca2+ enhance the surface membrane expression of a small-conductance Ca2+-activated K+ (SK2) channel. Proc Natl Acad Sci U S A (2014) 0.89
Shear stress triggers insertion of voltage-gated potassium channels from intracellular compartments in atrial myocytes. Proc Natl Acad Sci U S A (2013) 0.87
Trafficking of intermediate (KCa3.1) and small (KCa2.x) conductance, Ca(2+)-activated K(+) channels: a novel target for medicinal chemistry efforts? ChemMedChem (2012) 0.86
Polycomb-dependent repression of the potassium channel-encoding gene KCNA5 promotes cancer cell survival under conditions of stress. Oncogene (2014) 0.81
Improved functional expression of human cardiac kv1.5 channels and trafficking-defective mutants by low temperature treatment. PLoS One (2014) 0.75
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
Endocytic recycling. Nat Rev Mol Cell Biol (2004) 10.87
Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol (2003) 9.85
Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med (1995) 7.83
Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation (2005) 6.68
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet (2006) 3.15
Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res (1993) 2.71
Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation (2005) 2.61
Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res (2003) 2.27
Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA (1985) 2.00
Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov (2006) 1.98
Rab GTPases and myosin motors in organelle motility. Traffic (2004) 1.95
Isoform-specific localization of voltage-gated K+ channels to distinct lipid raft populations. Targeting of Kv1.5 to caveolae. J Biol Chem (2000) 1.82
A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need. Am Heart J (2006) 1.79
Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther (2004) 1.76
Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers. An effect on steady state sodium currents? Circ Res (1982) 1.75
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol (2006) 1.68
Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol (2002) 1.63
Prevalence of asymptomatic recurrences of atrial fibrillation after successful radiofrequency catheter ablation. J Cardiovasc Electrophysiol (2004) 1.62
The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J Biol Chem (2001) 1.60
Myosin-V, a versatile motor for short-range vesicle transport. Traffic (2002) 1.54
Rabs, Rips, FIPs, and endocytic membrane traffic. ScientificWorldJournal (2003) 1.51
Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol (1996) 1.50
K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. J Pharmacol Exp Ther (1994) 1.50
Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J Am Coll Cardiol (2001) 1.46
Targeted replacement of KV1.5 in the mouse leads to loss of the 4-aminopyridine-sensitive component of I(K,slow) and resistance to drug-induced qt prolongation. Circ Res (2001) 1.45
Cooperation between microtubule- and actin-based motor proteins. Annu Rev Cell Dev Biol (1999) 1.45
Functional differences in Kv1.5 currents expressed in mammalian cell lines are due to the presence of endogenous Kv beta 2.1 subunits. J Biol Chem (1996) 1.40
SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5. Proc Natl Acad Sci U S A (2007) 1.39
Kv1.5 surface expression is modulated by retrograde trafficking of newly endocytosed channels by the dynein motor. Circ Res (2005) 1.37
Localization of the Kv1.5 K+ channel protein in explanted cardiac tissue. J Clin Invest (1995) 1.35
Rab-GTPase-dependent endocytic recycling of Kv1.5 in atrial myocytes. J Biol Chem (2007) 1.34
Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels. J Biol Chem (2003) 1.30
Co-chaperone FKBP38 promotes HERG trafficking. J Biol Chem (2007) 1.30
Potassium channel ontogeny. Annu Rev Physiol (2002) 1.27
Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J Pharmacol Exp Ther (2007) 1.27
PATIENTS WITH MITRAL STENOSIS AND SYSTEMIC EMBOLI; HEMODYNAMIC AND CLINICAL OBSERVATIONS. Arch Intern Med (1964) 1.26
A novel K+ channel beta-subunit (hKv beta 1.3) is produced via alternative mRNA splicing. J Biol Chem (1995) 1.24
Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol (2005) 1.23
Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes. J Physiol (2007) 1.22
Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. Mol Pharmacol (2006) 1.19
Assembly of mammalian voltage-gated potassium channels: evidence for an important role of the first transmembrane segment. Neuron (1994) 1.18
The birth of a channel. Neuron (2003) 1.18
Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5. Circ Res (2009) 1.15
Coupled tertiary folding and oligomerization of the T1 domain of Kv channels. Neuron (2005) 1.13
hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans (2007) 1.12
[ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary]. Rev Port Cardiol (2007) 1.10
Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br J Pharmacol (2007) 1.09
alpha-actinin-2 couples to cardiac Kv1.5 channels, regulating current density and channel localization in HEK cells. FEBS Lett (2000) 1.09
Mechanisms of cardiac potassium channel trafficking. J Physiol (2007) 1.09
Endocytosis and sorting of glycosphingolipids in sphingolipid storage disease. Trends Cell Biol (2002) 1.08
Caveolin-3 and SAP97 form a scaffolding protein complex that regulates the voltage-gated potassium channel Kv1.5. Am J Physiol Heart Circ Physiol (2004) 1.06
Modulation of the voltage-gated potassium channel Kv1.5 by the SGK1 protein kinase involves inhibition of channel ubiquitination. Cell Physiol Biochem (2008) 1.06
Distinct domains of the voltage-gated K+ channel Kv beta 1.3 beta-subunit affect voltage-dependent gating. Am J Physiol (1998) 1.06
Progress in nonpharmacologic therapy of atrial fibrillation. J Cardiovasc Electrophysiol (2003) 1.05
Protein kinase A phosphorylation alters Kvbeta1.3 subunit-mediated inactivation of the Kv1.5 potassium channel. J Biol Chem (1999) 1.04
Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf (2010) 1.03
Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol (2007) 1.02
Cholesterol modulates the recruitment of Kv1.5 channels from Rab11-associated recycling endosome in native atrial myocytes. Proc Natl Acad Sci U S A (2009) 1.01
Posttranslational modification of voltage-dependent potassium channel Kv1.5: COOH-terminal palmitoylation modulates its biological properties. Am J Physiol Heart Circ Physiol (2008) 1.00
New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc Pharmacol (2008) 0.99
Assembly with the Kvbeta1.3 subunit modulates drug block of hKv1.5 channels. Mol Pharmacol (2002) 0.99
The anchoring protein SAP97 retains Kv1.5 channels in the plasma membrane of cardiac myocytes. Am J Physiol Heart Circ Physiol (2008) 0.99
Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extraostial ablation strategy. Am Heart J (2006) 0.97
Hypoxic pulmonary vasoconstriction: role of voltage-gated potassium channels. Respir Res (2000) 0.97
S-acylation regulates Kv1.5 channel surface expression. Am J Physiol Cell Physiol (2007) 0.96
Phosphorylation is required for alteration of kv1.5 K(+) channel function by the Kvbeta1.3 subunit. J Biol Chem (1999) 0.96
HERG channel trafficking. Novartis Found Symp (2005) 0.95
Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol (2008) 0.94
Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies. Mayo Clin Proc (2009) 0.93
Modulation of Kv1.5 currents by protein kinase A, tyrosine kinase, and protein tyrosine phosphatase requires an intact cytoskeleton. Mol Pharmacol (2002) 0.93
Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest (2005) 0.93
hERG: protein trafficking and potential for therapy and drug side effects. Curr Opin Drug Discov Devel (2010) 0.91
SAP97 increases Kv1.5 currents through an indirect N-terminal mechanism. FEBS Lett (2003) 0.89
Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valines. Br J Pharmacol (2003) 0.88
A specific N-terminal residue in Kv1.5 is required for upregulation of the channel by SAP97. Biochem Biophys Res Commun (2006) 0.87
Localization and trafficking of cardiac voltage-gated potassium channels. Biochem Soc Trans (2007) 0.86
Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Curr Med Chem Cardiovasc Hematol Agents (2003) 0.86
Modulation of the human Kv1.5 channel by protein kinase C activation: role of the Kvbeta1.2 subunit. J Pharmacol Exp Ther (2002) 0.85
Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now? Heart Rhythm (2004) 0.84
Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: comparison with quinidine and dofetilide. J Pharmacol Exp Ther (1997) 0.84
Nonpharmacologic strategies: the evolving story of ablation and hybrid therapy. Am J Cardiol (2008) 0.84
Evidence for proteasomal degradation of Kv1.5 channel protein. Biochem Biophys Res Commun (2005) 0.84
Functional studies of individual myosin molecules. Ann N Y Acad Sci (2006) 0.83
The pathobiology of pulmonary hypertension. Smooth muscle cells and ion channels. Clin Chest Med (2001) 0.80
Potassium channels in atrial fibrillation: targets for atrial and pathology-specific therapy? Heart Rhythm (2007) 0.80
Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation. ChemMedChem (2008) 0.76
Electrical and pharmacologic cardioversion for atrial fibrillation. Med Clin North Am (2008) 0.76
Ciliary entry of the kinesin-2 motor KIF17 is regulated by importin-beta2 and RanGTP. Nat Cell Biol (2010) 2.66
Ciliary targeting of olfactory CNG channels requires the CNGB1b subunit and the kinesin-2 motor protein, KIF17. Curr Biol (2006) 2.36
Hypomorphic CEP290/NPHP6 mutations result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons. Proc Natl Acad Sci U S A (2007) 1.74
Remodeling of mechanical junctions and of microtubule-associated proteins accompany cardiac connexin43 lateralization. Heart Rhythm (2012) 1.69
Dynamic reciprocity of sodium and potassium channel expression in a macromolecular complex controls cardiac excitability and arrhythmia. Proc Natl Acad Sci U S A (2012) 1.58
Maxi-K channels localize to caveolae in human myometrium: a role for an actin-channel-caveolin complex in the regulation of myometrial smooth muscle K+ current. Am J Physiol Cell Physiol (2005) 1.40
SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5. Proc Natl Acad Sci U S A (2007) 1.39
PIP3 controls synaptic function by maintaining AMPA receptor clustering at the postsynaptic membrane. Nat Neurosci (2009) 1.36
Rab-GTPase-dependent endocytic recycling of Kv1.5 in atrial myocytes. J Biol Chem (2007) 1.34
Functional role of lipid raft microdomains in cyclic nucleotide-gated channel activation. Mol Pharmacol (2004) 1.21
Interplay between PIP3 and calmodulin regulation of olfactory cyclic nucleotide-gated channels. Proc Natl Acad Sci U S A (2006) 1.19
Heme regulatory motifs in heme oxygenase-2 form a thiol/disulfide redox switch that responds to the cellular redox state. J Biol Chem (2009) 1.18
Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5. Circ Res (2009) 1.15
Induction of Ran GTP drives ciliogenesis. Mol Biol Cell (2011) 1.13
Localization of ion channels to lipid Raft domains within the cardiovascular system. Trends Cardiovasc Med (2004) 1.09
Combining Cep290 and Mkks ciliopathy alleles in mice rescues sensory defects and restores ciliogenesis. J Clin Invest (2012) 1.09
Gene therapy rescues cilia defects and restores olfactory function in a mammalian ciliopathy model. Nat Med (2012) 1.05
Olfactory cilia: linking sensory cilia function and human disease. Chem Senses (2009) 1.04
Olfactory cilia: our direct neuronal connection to the external world. Curr Top Dev Biol (2008) 1.00
S-acylation regulates Kv1.5 channel surface expression. Am J Physiol Cell Physiol (2007) 0.96
Differential effect of membrane cholesterol removal on mu- and delta-opioid receptors: a parallel comparison of acute and chronic signaling to adenylyl cyclase. J Biol Chem (2009) 0.96
Ordered assembly of the adhesive and electrochemical connections within newly formed intercalated disks in primary cultures of adult rat cardiomyocytes. J Biomed Biotechnol (2010) 0.96
The AP-1 clathrin adaptor facilitates cilium formation and functions with RAB-8 in C. elegans ciliary membrane transport. J Cell Sci (2010) 0.95
PACS-1 mediates phosphorylation-dependent ciliary trafficking of the cyclic-nucleotide-gated channel in olfactory sensory neurons. J Neurosci (2009) 0.95
Caveolin regulates kv1.5 trafficking to cholesterol-rich membrane microdomains. Mol Pharmacol (2007) 0.93
Redox-sensitive sulfenic acid modification regulates surface expression of the cardiovascular voltage-gated potassium channel Kv1.5. Circ Res (2012) 0.92
Kv channel subunits that contribute to voltage-gated K+ current in renal vascular smooth muscle. Pflugers Arch (2003) 0.90
Role for myosin-V motor proteins in the selective delivery of Kv channel isoforms to the membrane surface of cardiac myocytes. Circ Res (2014) 0.85
Modulation of the atrial specific Kv1.5 channel by the n-3 polyunsaturated fatty acid, alpha-linolenic acid. J Mol Cell Cardiol (2007) 0.85
Subunit-dependent axonal trafficking of distinct alpha heteromeric potassium channel complexes. J Neurosci (2011) 0.82
Smelling the roses and seeing the light: gene therapy for ciliopathies. Trends Biotechnol (2013) 0.82
Redox, haem and CO in enzymatic catalysis and regulation. Biochem Soc Trans (2012) 0.82
Antifibrillatory agents and potassium channels in the atria: pore block versus channel trafficking. Mol Interv (2009) 0.79